Overview
Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial
Description
doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound
Eligibility
Inclusion Criteria:
- Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial
Exclusion Criteria:
- Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm